Segments - Schedule of Segment Reporting Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating expenses:
Segment loss	$ 58,935	$ 52,392
Reconciliation of segment loss
Interest and other (income) expense, net	(3,568)	(5,882)
Interest expense	799	445
Net loss	56,166	46,955
Reportable Segment
Operating expenses:
Bexotegrast - clinical trial and third party contracting costs	21,589	17,217
Employee-related expenses - research and development (excluding stock-based compensation)	10,486	9,138
General and administrative costs (excluding stock-based compensation)	10,289	8,650
Other segment items	16,571	17,387
Segment loss	58,935	52,392
Reconciliation of segment loss
Interest and other (income) expense, net	(3,568)	(5,882)
Interest expense	799	445
Net loss	$ 56,166	$ 46,955